Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Overview

The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

Full Title of Study: “Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (LEAP-SE): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Sertraline Versus Escitalopram in Adults With Major Depressive Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 30, 2023

Detailed Description

The LEAP-SE study is an 8-week, multicenter, randomized, blinded study to evaluate the performance of EEG-based biomarkers in predicting treatment outcome. Study participants will be randomized in a 1:1 ratio to receive either sertraline or escitalopram and followed for 8 weeks.

Interventions

  • Drug: Sertraline
    • FDA approved antidepressant
  • Drug: Escitalopram
    • FDA approved antidepressant

Arms, Groups and Cohorts

  • Experimental: Sertraline
    • Sertraline 100-200 mg daily for 8 weeks
  • Active Comparator: Escitalopram
    • Escitalopram 10-20 mg daily for 8 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score
    • Time Frame: 8 weeks
    • Response rate will be calculated as the percentage of participants meeting response criteria (>50% reduction from baseline QIDS-SR total score at 8-week endpoint). The QIDS-SR is a 16-item, participant-rated short form of the Inventory of Depressive Symptomatology that assesses 9 domains: sad mood, concentration, self-outlook, suicidal ideation, involvement, energy/fatigability, sleep disturbance, appetite/weight increase/decrease and psychomotor agitation/retardation. Scores range from 0 (none) to 27 (very severe). The QIDS-SR total score was used to derive the mean change from baseline to endpoint depression.

Secondary Measures

  • Percentage decrease in depressive symptoms on the patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score
    • Time Frame: 8 weeks
    • Quick Inventory of Depressive Symptoms (QIDS-SR)
  • Absolute score decrease from baseline to the week 8 endpoint on the QIDS-SR as a function of biomarker score
    • Time Frame: 8 weeks
    • Quick Inventory of Depressive Symptoms (QIDS-SR)

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female, aged 22 or older at the time of informed consent. – Diagnosis of Major Depressive Disorder (MDD) based on the Structured Clinical Interview for DSM-5 for depression. – Moderate or severe depression on DSM-5 depression criteria items, as assessed by a score of 10 or more on the Patient Health Questionnaire (PHQ-9) – Has not taken either study medications (sertraline, escitalopram) in the current episode – Has not received electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), or esketamine treatment in the current episode – Provision of personally signed and dated written informed consent prior to any study procedures – Agrees to, and is eligible for all biomarker assessments (EEG, neurocognitive testing, activity and sleep monitoring, genetic testing) – Fluent in English – Ability to complete all assessments independently – Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria:

  • Diagnosis of bipolar disorder or a psychotic disorder based on the Structured Clinical Interview for DSM-5. – Concurrent use of antidepressants, antipsychotics or mood stabilizers – Use of hypnotics, anxiolytics or opiate pain medications greater than three days per week and unable to reduce use to three or fewer days per week on an as needed basis – Pregnant or breastfeeding – Severe impediment to vision, hearing, comprehension, and/or hand movement that interferes with study tasks – Active substance use that interferes with ability to consent and/or complete assessments – Any contraindication to EEG (e.g. requiring high concentration oxygen) – Employees/family of employees of clinic site – Participation in another research study within 2 months prior to the first study visit

Gender Eligibility: All

Minimum Age: 22 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alto Neuroscience
  • Collaborator
    • National Institute of Mental Health (NIMH)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Corey Keller, MD, PhD, Study Director, Alto Neuroscience

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.